Hadassah University Medical Center
Jerusalem, Israel
NCT Number: NCT05921461
Feasibility, usability and safety clinical study that is aimed at testing of the non-invasive VOTIS PedCheck system for measurement of changes in absorption of light in order to derive changes in perfusion and oxygen levels in the foot.
Looking for future studies?
Notify Me40 year and older
All sexes
Observational
Jerusalem, Israel
Introduction:
Peripheral Arterial Disease (PAD) affects 8-12 million people in the United States, and approximately 230 million worldwide. When linked with diabetes, PAD results in over 71,000 amputations annually.
Patients with PAD have decreased lower extremity arterial perfusion which is commonly referred to as "poor circulation." In most cases of PAD, atherosclerotic plaques narrow the arterial flow lumen which restricts blood flow to the distal extremity. This condition is characterized by progressive vessel obstructions, associated with cardiovascular (CV) events, including myocardial infarction (MI), stroke, limb ischemia, and CV death. Although PAD is a prevalent condition, it is still considered as an underdiagnosed manifestation of atherosclerosis. PAD is one of the most common vascular complications of diabetes, and can cause foot ischemia which is associated with non healing wounds, gangrene and amputations. At present there is no gold standard or test/device to identify, evaluate, and monitor the circulatory health of the foot in a reliable and precise way. In addition, calcification of blood vessels in patients with diabetes complicates the evaluation of perfusion in the foot. Since diabetes has reached epidemic proportions (60M people affected in Europe), there is an urgent need for additional measurement tools for assistance for the evaluation of PAD complications.
The current study is aimed at feasibility, usability and safety testing of the non-invasive VOTIS PedCheck system as an assessment tool of PAD. The protocol allows for 30 PAD patients and 30 self assessed healthy controls.
Objectives:
Secondary objective:
Description of investigational product:
Votis PedCheck portable device comprises patches affixed to the foot with encased laser diodes and photodetector sensors that automatically measure absorption of the light. Via lightweight leads, the patches link to a central control and display device. In addition an inflatable blood pressure cuff is placed above the knee. The control device sets the inflation and deflation of the cuff according to the protocol.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Control group Inclusion Criteria:
Control group exclusion Criteria:
PAD group Inclusion Criteria:
PAD group exclusion Criteria:
Time frame: Through study completion, an average of 1 year.
Observation of adverse skin changes or tissue damage or reports of discomfort.
Time frame: Through study completion, an average of 1 year.
HOVR score 0-100. 0-40 being no PAD, 40-100 being increasingly severe PAD.
Time frame: Through study completion, an average of 1 year.
Usability will be evaluated by standard usability patient and operator questionnaires for scoring convenience. Convenience will be rated by numerical rating scale for scoring convenience 0-5 where 0 represents very hard and 5 very easy.
Time frame: Through study completion, an average of 1 year.
Usability will be evaluated by Numerical rating scale for scoring pain. 0-10 where 0 represents no pain and 10 the most severe.
Votis Subdermal Imaging Technologies LTD
Industry
The Use of Hemodynamic Occlusive and Vascular Response (HOVR) Technology for the Measurement of Absorption of Light in Order to Derive Changes of Perfusion and Oxygen Levels in the Foot.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02791204
Arterial Occlusive Diseases, Arteriosclerosis
New Haven, Connecticut, United States
View Trial DetailsNCT06753604
Arterial Occlusive Diseases, Arteriosclerosis
Izmir, Turkey (Türkiye)
View Trial DetailsNCT03253328
Arterial Occlusive Diseases, Arteriosclerosis
St Louis, Missouri, United States
View Trial DetailsNCT03085524
Arterial Occlusive Diseases, Arteriosclerosis
Long Beach, California, United States
View Trial Details